AAAAAA
Results:
1-16
|
Results: 16
Authors:
Pickens, RW
Preston, KL
Miles, DR
Gupman, AE
Johnson, EO
Newlin, DB
Soriano, J
van den Bree, MBM
Umbricht, A
Citation: Rw. Pickens et al., Family history influence on drug abuse severity and treatment outcome, DRUG AL DEP, 61(3), 2001, pp. 261-270
Authors:
Spanbauer, AC
Casseday, S
Davoudzadeh, D
Preston, KL
Huestis, MA
Citation: Ac. Spanbauer et al., Detection of opiate use in a methadone maintenance treatment population with the CEDIA (R) 6-acetyl morphine and CEDIA DAU opiate assays, J ANAL TOX, 25(7), 2001, pp. 515-519
Authors:
Preston, KL
Umbricht, A
Wong, CJ
Epstein, DH
Citation: Kl. Preston et al., Shaping cocaine abstinence by successive approximation, J CONS CLIN, 69(4), 2001, pp. 643-654
Authors:
Huestis, MA
Gorelick, DA
Heishman, SJ
Preston, KL
Nelson, RA
Moolchan, ET
Frank, RA
Citation: Ma. Huestis et al., Blockade of effects of smoked marijuana by the CBl-selective cannabinoid receptor antagonist SR141716, ARCH G PSYC, 58(4), 2001, pp. 322-328
Authors:
Robles, E
Silverman, K
Preston, KL
Cone, EJ
Katz, E
Bigelow, GE
Stitzer, ML
Citation: E. Robles et al., The brief abstinence test: voucher-based reinforcement of cocaine abstinence, DRUG AL DEP, 58(1-2), 2000, pp. 205-212
Authors:
Moolchan, ET
Cone, EJ
Wstadik, A
Huestis, MA
Preston, KL
Citation: Et. Moolchan et al., Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: Plasma and saliva analysis, J ANAL TOX, 24(7), 2000, pp. 458-466
Authors:
Huestis, MA
Cone, EJ
Wong, CJ
Umbricht, A
Preston, KL
Citation: Ma. Huestis et al., Monitoring opiate use in substance abuse treatment patients with sweat andurine drug testing, J ANAL TOX, 24(7), 2000, pp. 509-521
Authors:
Preston, KL
Bigelow, GE
Citation: Kl. Preston et Ge. Bigelow, Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination, J PHARM EXP, 295(1), 2000, pp. 114-124
Authors:
Preston, KL
Umbricht, A
Epstein, DH
Citation: Kl. Preston et al., Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance, ARCH G PSYC, 57(4), 2000, pp. 395-404
Authors:
Hall, GW
Carriero, NJ
Takushi, RY
Montoya, ID
Preston, KL
Gorelick, DA
Citation: Gw. Hall et al., Pathological gambling among cocaine-dependent outpatients, AM J PSYCHI, 157(7), 2000, pp. 1127-1133
Authors:
Epstein, DH
Silverman, K
Henningfield, JE
Preston, KL
Citation: Dh. Epstein et al., Low-dose oral cocaine in humans: acquisition of discrimination and time-course of effects, BEHAV PHARM, 10(5), 1999, pp. 531-542
Authors:
Umbricht, A
Montoya, ID
Hoover, DR
Demuth, KL
Chiang, CT
Preston, KL
Citation: A. Umbricht et al., Naltrexone shortened opioid detoxification with buprenorphine, DRUG AL DEP, 56(3), 1999, pp. 181-190
Authors:
Preston, KL
Silverman, K
Umbricht, A
DeJesus, A
Montoya, ID
Schuster, CR
Citation: Kl. Preston et al., Improvement in naltrexone treatment compliance with contingency management, DRUG AL DEP, 54(2), 1999, pp. 127-135
Authors:
Preston, KL
Huestis, MA
Wong, CJ
Umbricht, A
Goldberger, BA
Cone, EJ
Citation: Kl. Preston et al., Monitoring cocaine use in substance-abuse-treatment patients by sweat and urine testing, J ANAL TOX, 23(5), 1999, pp. 313-322
Authors:
Jones, HE
Bigelow, GE
Preston, KL
Citation: He. Jones et al., Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure, J PHARM EXP, 289(3), 1999, pp. 1350-1361
Authors:
Preston, KL
Bigelow, GE
Citation: Kl. Preston et Ge. Bigelow, Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose, BEHAV PHARM, 9(7), 1998, pp. 533-543
Risultati:
1-16
|